(MENAFN- GetNews) Cancer Biological Therapy Market Size, Growth and Insights By Phases (Phase I, Phases II and Phases III); Type (Monoclonal Antibodies, Interferon's, Interleukins, Cancer growth inhibitors, and others); End-Users - Forecast to 2023
The global COVID-19 Impact on Cancer Biological Therapy Market report by Market Research Future (MRFR) asserts that market size is anticipated to reach a value of USD 82,276.8 million by 2023. It is projected to exhibit a CAGR of 4.7% over the forecast period. Cancer biological therapy is a type of treatment for various cancers by enhancing the immunity system. The increasing prevalence of cancer globally and its low outcome due to current treatment methods can drive the use of this method. The outbreak of the COVID-19 virus and its impact on the industry during the forecast period has been assesses as well.
The cancer biological therapy market is driven by the establishment of cancer treatment facilities, preference for biological therapy, and huge prevalence of cancer cases. Low number of side-effects as well as high success rate for treating first-stage cancer outcomes by 35% can fuel the cancer biological therapy market growth.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/566
The change in lifestyles of consumers and rise in smoking in the Middle East can spur the cancer biological therapy market demand for biological therapy. According to a study in the Economist, an average Lebanese smoked close to 2,379 cigarettes. The outbreak of the COVID-19 virus can pose a risk to cancer patients and drive the need for therapy method. According to the National Center for Biotechnology Information (NCBI), 39% of patients with cancer have a possibility of contracting COVID-19. It has affected the production of immunotherapy drugs and created a lag in active pharmaceutical ingredients (APIs) production. But high costs of treatment and large number of risks pose a challenge to the market growth.
Cancer Biological Therapy Market Segmentation:
The global cancer biological therapy market is segmented by phases, type, and end-users.
Based on the phases, the market has been segmented as phase I, phase II, and phase III.
By type, the cancer biological therapy market has been segmented into cancer growth inhibitors, colony-stimulating factors, monoclonal antibodies, interferons, interleukins, and gene therapy. Monoclonal antibodies accounted for the largest market share in 2016 with a value pegged at USD 16,957.1 million in 2016. On the other hand, colony-stimulating factors can display a CAGR of 5.2% over the assessment period.
By end-users, the cancer biological therapy market has been segmented into laboratories, hospitals & clinics, and cancer research centers. Cancer research centers are estimated to exhibit a CAGR of 5.2% over the forecast period.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/report/covid-19-impact-cancer-biological-therapy-market
Cancer Biological Therapy Market Regional Analysis
North America, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) are regions considered with respect to the global cancer biological therapy market.
North America is expected to lead in the global cancer biological therapy market due to investments in cancer research and immunotherapy. The U.S. accounts for the maximum market share in the region due to favorable reimbursement schemes and greater expenditure on healthcare. Europe is the second largest market owing to large disposable income levels of patients and rising awareness levels.
APAC will be the fastest region due to large unmet needs which will be led by China and India. Medical tourism prevalent in these countries, a large patient pool, and need for effective treatment methods can drive the regional market growth. Lastly, the MEA biological therapy market will be led by the gulf nations of Saudi Arabia and the UAE.
Cancer Biological Therapy Market Competition Outlook
Bristol-Myers Squibb, Amgen Inc., Pfizer Inc., Merck & Co., Inc., F. Hoffmann-La Roche AG, Novartis, EnGeneIC Ltd, Celgene Corporation, Eli Lilly and Company, and others are key players of the global cancer biological therapy industry
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/cancer-biologic-therapy-market-566
MENAFN2606202000703268ID1100393211
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.